CN119241692A - Hiv疫苗免疫原 - Google Patents

Hiv疫苗免疫原 Download PDF

Info

Publication number
CN119241692A
CN119241692A CN202411139072.4A CN202411139072A CN119241692A CN 119241692 A CN119241692 A CN 119241692A CN 202411139072 A CN202411139072 A CN 202411139072A CN 119241692 A CN119241692 A CN 119241692A
Authority
CN
China
Prior art keywords
antibody
seq
nos
hiv
glycan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411139072.4A
Other languages
English (en)
Chinese (zh)
Inventor
米歇尔·努森兹韦格
帕梅拉·J·比约克曼
A·埃斯科拉诺
H·格里斯蒂克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
California Institute of Technology
Original Assignee
Rockefeller University
California Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, California Institute of Technology filed Critical Rockefeller University
Publication of CN119241692A publication Critical patent/CN119241692A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202411139072.4A 2018-12-04 2019-11-27 Hiv疫苗免疫原 Pending CN119241692A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862775192P 2018-12-04 2018-12-04
US62/775,192 2018-12-04
CN201980090856.3A CN113454100B (zh) 2018-12-04 2019-11-27 Hiv疫苗免疫原
PCT/US2019/063619 WO2020117590A1 (en) 2018-12-04 2019-11-27 Hiv vaccine immunogens

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980090856.3A Division CN113454100B (zh) 2018-12-04 2019-11-27 Hiv疫苗免疫原

Publications (1)

Publication Number Publication Date
CN119241692A true CN119241692A (zh) 2025-01-03

Family

ID=70974318

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411139072.4A Pending CN119241692A (zh) 2018-12-04 2019-11-27 Hiv疫苗免疫原
CN201980090856.3A Active CN113454100B (zh) 2018-12-04 2019-11-27 Hiv疫苗免疫原

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980090856.3A Active CN113454100B (zh) 2018-12-04 2019-11-27 Hiv疫苗免疫原

Country Status (10)

Country Link
US (2) US12239698B2 (https=)
EP (2) EP3891170B1 (https=)
JP (2) JP7483234B2 (https=)
KR (1) KR20210124205A (https=)
CN (2) CN119241692A (https=)
AU (2) AU2019393745B2 (https=)
CA (1) CA3120324A1 (https=)
ES (1) ES2993834T3 (https=)
PL (1) PL3891170T3 (https=)
WO (1) WO2020117590A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732898B (zh) * 2022-04-01 2023-05-09 中国人民解放军军事科学院军事医学研究院 一种CpG佐剂与抗原定点共价结合方法
WO2024130122A2 (en) * 2022-12-15 2024-06-20 The Wistar Institute Of Anatomy And Biology Hiv immunogens and methods of using same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
RO116459B1 (ro) 1991-07-25 2001-02-28 Idec Pharma Corp Compozitie imunogena
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
DE69311538D1 (de) 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2003020904A2 (en) 2001-08-31 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of generating human cd4+ th1 cells
US8673307B1 (en) * 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
SI3260136T1 (sl) * 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
EP2765138B1 (en) * 2012-11-05 2018-01-10 International Aids Vaccine Initiative HIV-1 envelope glycoprotein
US10106583B2 (en) * 2014-03-07 2018-10-23 Cornell University Materials and methods for producing cleaved, HIV-1 envelope glycoprotein trimers
ES2789348T3 (es) 2015-03-20 2020-10-26 Us Health Anticuerpos neutralizantes para GP120 y sus usos
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
WO2017055522A1 (en) * 2015-09-29 2017-04-06 Academisch Medisch Centrum Stabilized env proteins of hiv
WO2018161049A1 (en) * 2017-03-03 2018-09-07 Duke University Compositions and methods for inducing hiv-1 antibodies
WO2017165674A1 (en) * 2016-03-23 2017-09-28 International Aids Vaccine Initiative Immunogenic trimers
WO2019169356A1 (en) * 2018-03-02 2019-09-06 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies

Also Published As

Publication number Publication date
US12239698B2 (en) 2025-03-04
EP3891170C0 (en) 2024-07-31
US20250144197A1 (en) 2025-05-08
CA3120324A1 (en) 2020-06-11
AU2019393745A1 (en) 2021-06-10
CN113454100A (zh) 2021-09-28
EP3891170B1 (en) 2024-07-31
EP4464380A3 (en) 2025-05-07
EP3891170A1 (en) 2021-10-13
JP7483234B2 (ja) 2024-05-15
JP2022513438A (ja) 2022-02-08
US20220031830A1 (en) 2022-02-03
AU2025242201A1 (en) 2026-01-15
JP2024099671A (ja) 2024-07-25
AU2019393745B2 (en) 2025-08-07
KR20210124205A (ko) 2021-10-14
ES2993834T3 (en) 2025-01-10
CN113454100B (zh) 2024-08-23
EP4464380A2 (en) 2024-11-20
WO2020117590A1 (en) 2020-06-11
EP3891170A4 (en) 2022-12-07
PL3891170T3 (pl) 2024-12-02

Similar Documents

Publication Publication Date Title
JP7536737B2 (ja) Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
US20250144197A1 (en) Hiv vaccine immunogens
US12053520B2 (en) Glycan-masked engineered outer domains of HIV-1 gp120 and their use
TW201041593A (en) Cancer antigen helper peptide
JP2019126343A (ja) 生体外での効率的な定向増幅用のキメラ抗原受容体及びその適用
CA2711145A1 (en) Immunomodulating compositions and uses therefor
RS53769B1 (sr) Imunogena jedinjenja koja sadrže hiv gp41 peptid spojen na crm197 belančevinu-nosioc
TW202208400A (zh) 來自ｓａｒｓ–ｃｏｖ–２之保守肽抗原決定基於開發廣泛型ｃｏｖｉｄ–１９疫苗之用途
CN110054698A (zh) 抗cd19抗体的新型cd19-car载体的构建及应用
HK40119313A (en) Hiv vaccine immunogens
HK40119361A (zh) Hiv疫苗免疫原
HK40051015A (en) Hiv vaccine immunogens
HK40051015B (en) Hiv vaccine immunogens
HK40053334A (en) Hiv vaccine immunogens
CA3243906A1 (en) RHINOVIRU VACCINE
HK40053334B (zh) Hiv疫苗免疫原
WO2019210782A1 (zh) 辅助性表位肽及其应用
US20240033341A1 (en) Hiv vaccine immunogens
TWI398262B (zh) 腫瘤相關抗原之免疫性肽類及其於癌症治療上的用途
WO2023015186A1 (en) Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
WO2025217530A1 (en) Hiv-1 immunogens and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40119361

Country of ref document: HK